Professional Perspectives On Addiction Medicine: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines
1441427333
9781441427335
Description:
This book is a collection of essays that offer the reader a comprehensive review of how neuroscience research has cast new light on the function of the human endogenous cannabinoid (EC) system and how cannabinoid-based medicines will be of significant therapeutic value in the not-so-distant future. Just as nicotine is not tobacco, or taxol is not yew tree bark, and digoxin is not foxglove, cannabinoids are not marijuana. By using powerful new research tools, the varied functions of the EC system are being elucidated and the potential for the development of novel new medications is now being described. And, as the reader will discover in the chapters ahead, we are clearly moving beyond the limitations and problems associated with medical marijuana and moving more toward cannabinoid-based medicines.
Best prices to buy, sell, or rent ISBN 9781441427335
Frequently Asked Questions about Professional Perspectives On Addiction Medicine: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines
The price for the book starts from $163.97 on Amazon and is available from 2 sellers at the moment.
If you’re interested in selling back the Professional Perspectives On Addiction Medicine: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the Professional Perspectives On Addiction Medicine: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines book, the best buyback offer comes from and is $ for the book in good condition.
The Professional Perspectives On Addiction Medicine: Beyond Medical Marijuana: Toward Cannabinoid-Based Medicines book is in very low demand now as the rank for the book is 11,211,998 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.